Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01486927




Registration number
NCT01486927
Ethics application status
Date submitted
19/11/2011
Date registered
7/12/2011
Date last updated
9/08/2016

Titles & IDs
Public title
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
Scientific title
A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study
Secondary ID [1] 0 0
2011-002393-23
Secondary ID [2] 0 0
CSL627_1001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hemophilia A 0 0
Condition category
Condition code
Blood 0 0 0 0
Clotting disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - rVIII-SingleChain
Treatment: Other - Octocog alfa

Experimental: Recombinant Factor VIII (rFVIII) -


Treatment: Other: rVIII-SingleChain
In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.

Treatment: Other: Octocog alfa
In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Treatment Success
Timepoint [1] 0 0
Up to 24 months
Primary outcome [2] 0 0
Inhibitor Formation to FVIII
Timepoint [2] 0 0
Up to 24 months
Primary outcome [3] 0 0
Annualized Spontaneous Bleeding Rate
Timepoint [3] 0 0
Up to 24 months
Primary outcome [4] 0 0
Treatment Success During the Peri-operative Surgical Sub-study
Timepoint [4] 0 0
From the start of surgery through the post-operative recovery (generally up to 14 days after surgery)
Secondary outcome [1] 0 0
AUC0-8 (Part 1)
Timepoint [1] 0 0
Before infusion and at up to 10 time points within 72 hours of infusion
Secondary outcome [2] 0 0
Cmax (Part 1)
Timepoint [2] 0 0
Before infusion and at up to 10 time points within 72 hours of infusion
Secondary outcome [3] 0 0
Tmax (Part 1)
Timepoint [3] 0 0
Before infusion and at up to 10 time points within 72 hours of infusion
Secondary outcome [4] 0 0
Half-life (t1/2) (Part 1)
Timepoint [4] 0 0
Before infusion and at up to 10 time points within 72 hours of infusion.
Secondary outcome [5] 0 0
Mean Residence Time (MRT) (Part 1)
Timepoint [5] 0 0
Before infusion and at up to 10 time points within 72 hours of infusion
Secondary outcome [6] 0 0
Clearance (Cl) (Part 1)
Timepoint [6] 0 0
Before infusion and at up to 10 time points within 72 hours of infusion
Secondary outcome [7] 0 0
Volume of Distribution at Steady-state (Vss) (Part 1)
Timepoint [7] 0 0
Before infusion and at up to 10 time points within 72 hours of infusion
Secondary outcome [8] 0 0
Incremental Recovery (Part 1)
Timepoint [8] 0 0
At 30 minutes after infusion
Secondary outcome [9] 0 0
Annualized Bleeding Rate for Total Bleeds and Traumatic Bleeds
Timepoint [9] 0 0
Up to 24 months
Secondary outcome [10] 0 0
Proportion of Bleeding Episodes Requiring 1, 2, 3 or > 3 Infusions of rVIII-SingleChain to Achieve Hemostasis
Timepoint [10] 0 0
During the study (up to 24 months; assessed at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24)

Eligibility
Key inclusion criteria
* Diagnosis of severe hemophilia A defined as <1% FVIII:C documented in medical records.
* Males between 18 and 65 years of age (Parts 1 and 2).
* Males between 12 and 65 years of age (Part 3).
* Subjects who have received or are currently receiving FVIII products (plasma-derived and/or recombinant FVIII) and have had >150 exposure days (EDs) with a FVIII product
* Written informed consent for study participation obtained before undergoing any study specific procedures.
Minimum age
12 Years
Maximum age
65 Years
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Any history of or current FVIII inhibitors
* Any first order family history of FVIII inhibitors
* Use of an Investigational Medicinal Product within 30 days prior to the first rVIII-SingleChain administration.
* Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain or reference product.
* Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein.
* Any known congenital or acquired coagulation disorder other than congenital FVIII deficiency.
* Platelet count < 100,000/µL at screening.
* Human immunodeficiency virus (HIV) positive subjects with a CD4 count < 200/mm3, in their medical history or at screening if available results are older than one year. (HIV positive subjects may participate in the study and antiviral therapy are permitted, at the discretion of the Investigator).
* Subject currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic corticosteroid treatment.
* Subject with serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) values > 5 times (x) the upper limit of normal (ULN) at Screening.
* Subjects with serum creatinine values > 2 x ULN at Screening.
* Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to Day 1.
* Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to Day 1.

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2014
Sample size
Target
Accrual to date
Final
175
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Study Site - Nedlands
Recruitment hospital [2] 0 0
Study Site - Perth
Recruitment postcode(s) [1] 0 0
WA 6009 - Nedlands
Recruitment postcode(s) [2] 0 0
WA 6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
United States of America
State/province [8] 0 0
Wisconsin
Country [9] 0 0
Austria
State/province [9] 0 0
Graz
Country [10] 0 0
Austria
State/province [10] 0 0
Vienna
Country [11] 0 0
Canada
State/province [11] 0 0
New Brunswick
Country [12] 0 0
Czech Republic
State/province [12] 0 0
Hradec Králové
Country [13] 0 0
Germany
State/province [13] 0 0
Berlin
Country [14] 0 0
Germany
State/province [14] 0 0
Bonn
Country [15] 0 0
Germany
State/province [15] 0 0
Gießen
Country [16] 0 0
Germany
State/province [16] 0 0
Hamburg
Country [17] 0 0
Germany
State/province [17] 0 0
Hannover
Country [18] 0 0
Germany
State/province [18] 0 0
Heidelberg
Country [19] 0 0
Hungary
State/province [19] 0 0
Debrecen
Country [20] 0 0
Italy
State/province [20] 0 0
Florence
Country [21] 0 0
Italy
State/province [21] 0 0
Milan
Country [22] 0 0
Italy
State/province [22] 0 0
Padova
Country [23] 0 0
Italy
State/province [23] 0 0
Torino
Country [24] 0 0
Japan
State/province [24] 0 0
Kashihara, Nara
Country [25] 0 0
Japan
State/province [25] 0 0
Kitakyushu, Fukuoka
Country [26] 0 0
Japan
State/province [26] 0 0
Nagoya
Country [27] 0 0
Japan
State/province [27] 0 0
Nishinomiya, Hyogo
Country [28] 0 0
Japan
State/province [28] 0 0
Okayama
Country [29] 0 0
Japan
State/province [29] 0 0
Saitama
Country [30] 0 0
Japan
State/province [30] 0 0
Suginami-ku, Tokyo
Country [31] 0 0
Japan
State/province [31] 0 0
Tokyo
Country [32] 0 0
Lebanon
State/province [32] 0 0
Beirut
Country [33] 0 0
Malaysia
State/province [33] 0 0
Kuala Lumpur
Country [34] 0 0
Netherlands
State/province [34] 0 0
Utrecht
Country [35] 0 0
Philippines
State/province [35] 0 0
Cebu City
Country [36] 0 0
Philippines
State/province [36] 0 0
Davao City
Country [37] 0 0
Poland
State/province [37] 0 0
Silesia
Country [38] 0 0
Poland
State/province [38] 0 0
Gdansk
Country [39] 0 0
Poland
State/province [39] 0 0
Krakow
Country [40] 0 0
Romania
State/province [40] 0 0
Bucharest
Country [41] 0 0
Russian Federation
State/province [41] 0 0
Barnaul
Country [42] 0 0
Russian Federation
State/province [42] 0 0
Kemerovo
Country [43] 0 0
South Africa
State/province [43] 0 0
Cape Town
Country [44] 0 0
South Africa
State/province [44] 0 0
Johannesburg
Country [45] 0 0
Spain
State/province [45] 0 0
Barcelona
Country [46] 0 0
Spain
State/province [46] 0 0
La Coruna
Country [47] 0 0
Spain
State/province [47] 0 0
Valencia
Country [48] 0 0
Ukraine
State/province [48] 0 0
Dnipropetrovsk
Country [49] 0 0
Ukraine
State/province [49] 0 0
Donetsk
Country [50] 0 0
Ukraine
State/province [50] 0 0
Lviv
Country [51] 0 0
United Kingdom
State/province [51] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
CSL Behring
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Program Director
Address 0 0
CSL Behring
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01486927